Global Intestine Cancer Therapeutics Market Insights 2029: Drivers, Challenges, and Revenue Forecast
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Predicted Market Size Of The Intestine Cancer Therapeutics Industry By 2029?
In the past few years, the market size of therapeutics for intestine cancer has significantly expanded. A growth from $14 billion in 2024 to $15.12 billion in 2025 is projected, indicating a compound annual growth rate (CAGR) of 8.0%. Factors such as breakthroughs in medical research, rise in cancer cases, adoption of chemotherapy and radiation therapies, initiatives for early detection and screening, as well as developments in genetic and biomarker findings have significantly contributed to the growth during the historical period.
The market size for therapeutics in intestine cancer is projected to experience significant expansion in the coming years, likely reaching a value of $20.88 billion by 2029, maintained by a compound annual growth rate (CAGR) of 8.4%. This predicted expansion during the forecast period is primarily due to advancements in immunotherapy, precision medicine, personalized treatments, the inception of targeted therapies, and the incorporation of artificial intelligence (AI) and patient-focused methodologies. Key trends foreseen during this forecast period encompass liquid biopsy technologies, precision medicine, biomarker research, combination therapies, patient-centered care and complementing therapies, with an increasing inclination toward minimally invasive surgical methods.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13231&type=smp
Which Industry Forces Are Driving The Intestine Cancer Therapeutics Market Forward?
The rise in the instance of hereditary colorectal cancer syndromes is anticipated to fuel the expansion of the intestine cancer therapeutics market. These are group of genetic disorders that enhance the likelihood of an individual contracting colorectal cancer (cancer of the colon or rectum). Such hereditary syndromes hold crucial importance in intestinal cancer therapeutics as they offer insights on unique genetic mutations that greatly heighten the risk of colorectal cancer. In line with a report from the World Health Organization, a Switzerland-based intergovernmental organization, by July 2023, the instances of hereditary colorectal cancer are forecasted to witness considerable growth by 2040, with an expected 3.2 million new cases and 1.6 million deaths per year. This translates into a rise of 63% in new cases and an increase of 73% in deaths compared to the existing rates. Hence, the growing instances of hereditary colorectal cancer syndromes are sparking off the growth of the intestine cancer therapeutics market.
What Is The Segment Breakdown Of The Intestine Cancer Therapeutics Market?
The intestine cancer therapeuticsmarket covered in this report is segmented –
1) By Treatment Type: Immunotherapy; Chemotherapy; Other Treatments
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
3) By Application: Hospitals; Homecare; Specialty Centers; Other Applications
Subsegments:
1) By Immunotherapy: Checkpoint Inhibitors; CAR T-Cell Therapy; Cancer Vaccines
2) By Chemotherapy: Adjuvant Chemotherapy; Neoadjuvant Chemotherapy; Palliative Chemotherapy
3) By Other Treatments: Targeted Therapy; Radiation Therapy; Surgery; Hormone Therapy
How Are Global Trends Impacting The Development Of The Intestine Cancer Therapeutics Market?
Leading corporations in the intestinal cancer treatment marketplace are innovating new products, such as Lonsurf, and acquiring approvals, in order to reach a wider customer base and enhance sales and revenue growth. LONSURF is a drug pairing, consisting of trifluridine and tipiracil, used for the treatment of metastatic colorectal cancer in adult patients. For example, in August 2023, the US-based pharmaceutical firm, Taiho Oncology Inc., was granted approval for Lonsurf by the US Food and Drug Administration. Lonsurf is dispensed in the form of a single oral tablet. Trifluridine functions by inhibiting the growth of cancer cells, while tipiracil boosts the effectiveness of trifluridine by stopping its breakdown in the body. The accreditation of Lonsurf grants access to patients with metastatic colorectal cancer, as well as other qualifying cancers, to a novel treatment alternative that could enhance the survival rates and life quality.
Which Companies Are Contributing Significantly To The Intestine Cancer Therapeutics Market Growth?
Major companies operating in the intestine cancer therapeutics market report are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report
Which Region Is Leading Innovation In The Intestine Cancer Therapeutics Market?
Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13231&type=smp
Browse Through More Reports Similar to the Global Intestine Cancer Therapeutics Market 2025, By The Business Research Company
Anti Inflammatory Therapeutics Global Market Report 2025
Small Cell Lung Cancer Therapeutics Global Market Report 2025
Duchenne Muscular Dystrophy Dmd Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
